VIM and neoplasm: Furthermore, treatment with TGFβ1 inhibitor, Disitertide, or TGFβ1 receptor inhibitor, LY-364947, significantly inhibited FAM3C expression (Figure 4F, s5B) in neutrophils, and reversed expression of E-cad and Vim in tumor cells (Figure 4G, s5C), respectively.